Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
Status:
Recruiting
Trial end date:
2028-04-28
Target enrollment:
Participant gender:
Summary
The DanNORMS study is phase 3 non-inferiority clinical trial examining whether treatment of
active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy
and safety.
Phase:
Phase 3
Details
Lead Sponsor:
Rigshospitalet, Denmark
Collaborators:
Aalborg University Hospital Aarhus University Hospital Danske Regioner GCP unit Odense University Hospital GCP unit, Copenhagen University Hospital GCP-unit at Aarhus University Hospital, Aarhus, Denmark Herlev Hospital Hillerod Hospital, Denmark Hospital of Central Denmark Region, Viborg, Denmark Hospital of South West Jutland, Esbjerg, Denmark Hospital of Southern Jutland, Sønderborg, Denmark Hvidovre University Hospital Kolding Sygehus Odense University Hospital Regional Hospital Holstebro Zealand University Hospital